Literature DB >> 11005445

The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression.

R Buttyan1, M A Ghafar, A Shabsigh.   

Abstract

Androgenic steroids are required to maintain the prostate gland in the adult state. Consistent with this requirement, androgen deprivation therapies typically induce a drastic regression of mature prostate tissue that is accompanied by the extensive loss of prostate cells through the programmed cell death process referred to as apoptosis. Whereas, in the past, the loss of prostate cells associated with androgen deprivation has generally been perceived to be a direct response of the androgen receptor-expressing prostate cells to an androgen-depleted environment, more recent studies of the prostate regression process suggest that it might instead be initiated by an indirect response of the prostatic parenchyma to an ischemic/hypoxic environment caused by a drastic reduction of blood flow to the tissue that occurs when androgens are withdrawn. This article reviews evidence that the prostatic vascular system is a primary target of androgen action and other evidence suggesting that the regression of the prostate parenchyma occurs secondarily to the regression of the prostate vascular system through cell death mediated by tissue ischemia/hypoxia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005445     DOI: 10.1097/00042307-200009000-00009

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  18 in total

1.  Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

Authors:  Yue Wu; Rishi Raj Chhipa; Jinrong Cheng; Haitao Zhang; James L Mohler; Clement Ip
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

2.  Downsizing and prostate cancer.

Authors:  Shandra Wilson
Journal:  Rev Urol       Date:  2004

3.  Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.

Authors:  Anthony J Usoro; Aniebietabasi S Obot; Itemobong S Ekaidem; Okon E Akaiso; Alphonsus E Udoh; O Akinloye
Journal:  Indian J Clin Biochem       Date:  2014-01-29

Review 4.  The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Michael W Drazer; Walter M Stadler
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

5.  Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate.

Authors:  Sietze Regter; Mohammad Hedayati; Yonggang Zhang; Haoming Zhou; Susan Dalrymple; Cameron J Koch; John T Isaacs; Theodore L DeWeese
Journal:  Prostate       Date:  2014-03-27       Impact factor: 4.104

Review 6.  NF-κB signaling in prostate cancer: a promising therapeutic target?

Authors:  Garima Jain; Marcus V Cronauer; Mark Schrader; Peter Möller; Ralf B Marienfeld
Journal:  World J Urol       Date:  2011-11-16       Impact factor: 4.226

7.  Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo.

Authors:  Fuminori Sato; Hiroshi Fukuhara; James P Basilion
Journal:  Neoplasia       Date:  2005-09       Impact factor: 5.715

8.  Androgen deprivation induces rapid involution and recovery of human prostate vasculature.

Authors:  Alejandro Godoy; Viviana P Montecinos; Danny R Gray; Paula Sotomayor; Jeffrey M Yau; R Robert Vethanayagam; Swaroop Singh; James L Mohler; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-10       Impact factor: 4.310

9.  Proliferating cell nuclear antigen (PCNA) overexpression and microvessel density predict survival in the urinary bladder carcinoma.

Authors:  Attalla F El-kott; Mahmoud A El-baz; Alaa A Mokhtar
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

10.  Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.